Qiagen (NYSE:QGEN) was upgraded by investment analysts at BNP Paribas from a “neutral” rating to an “outperform” rating in a report released on Friday, Briefing.com Automated Import reports.
QGEN has been the topic of several other reports. UBS Group reiterated a “sell” rating and issued a $220.00 price objective on shares of Tesla in a research report on Friday, March 15th. Deutsche Bank lowered shares of Ontex Group from a “buy” rating to a “hold” rating in a report on Wednesday, May 8th. Goldman Sachs Group lowered shares of JSR from a “neutral” rating to a “sell” rating in a report on Friday, June 21st. Wolfe Research began coverage on shares of Waters in a research note on Thursday, May 30th. They set an “underperform” rating for the company. Finally, Zacks Investment Research downgraded shares of Great Portland Estates from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $42.00.
Shares of Qiagen stock traded up $0.04 during trading on Friday, reaching $39.83. The company’s stock had a trading volume of 138,675 shares, compared to its average volume of 800,221. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.52 and a current ratio of 1.69. The company has a market capitalization of $9.02 billion, a price-to-earnings ratio of 29.72, a PEG ratio of 2.46 and a beta of 0.84. The stock has a 50-day moving average price of $39.51. Qiagen has a fifty-two week low of $32.33 and a fifty-two week high of $41.55.
Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.01. The company had revenue of $348.70 million for the quarter, compared to analysts’ expectations of $351.68 million. Qiagen had a net margin of 12.45% and a return on equity of 12.22%. Qiagen’s revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.26 EPS. As a group, sell-side analysts anticipate that Qiagen will post 1.43 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Xact Kapitalforvaltning AB increased its holdings in shares of Qiagen by 80.1% during the second quarter. Xact Kapitalforvaltning AB now owns 29,000 shares of the company’s stock valued at $1,176,000 after purchasing an additional 12,900 shares during the period. FMR LLC grew its holdings in Qiagen by 2,731.6% during the first quarter. FMR LLC now owns 2,548,771 shares of the company’s stock worth $103,518,000 after acquiring an additional 2,458,758 shares during the period. Diversified Trust Co acquired a new position in Qiagen during the first quarter worth about $922,000. Marshall Wace North America L.P. acquired a new position in Qiagen during the first quarter worth about $89,000. Finally, Marshall Wace LLP acquired a new position in Qiagen during the first quarter worth about $16,468,000. Hedge funds and other institutional investors own 63.22% of the company’s stock.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Read More: Why is total return important?
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.